(NASDAQ: ATYR) Atyr Pharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.8%.
Atyr Pharma's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast ATYR's revenue for 2025 to be $1,068,053,232, with the lowest ATYR revenue forecast at $1,068,053,232, and the highest ATYR revenue forecast at $1,068,053,232. On average, 2 Wall Street analysts forecast ATYR's revenue for 2026 to be $2,709,740,054, with the lowest ATYR revenue forecast at $2,402,229,728, and the highest ATYR revenue forecast at $3,017,250,380.
In 2027, ATYR is forecast to generate $4,018,550,285 in revenue, with the lowest revenue forecast at $1,780,088,720 and the highest revenue forecast at $6,257,011,851.